Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

NCT02939326 is registered in ClinicalTrials.gov with Bonti, Inc. as lead sponsor.

NCT NCT02939326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02939326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Lead sponsor
Bonti, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
July 12, 2017
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines (gl)